Smoking impact on CYP1A2 activity in a group of patients with schizophrenia (Q44683054)

5 December 2017

title

Smoking impact on CYP1A2 activity in a group of patients with schizophrenia (English)

1 reference

5 December 2017

0 references

Vasilis P Bozikas

1

1 reference

5 December 2017

Maria Papakosta

2

1 reference

5 December 2017

Ioannis Niopas

3

1 reference

5 December 2017

Athanasios Karavatos

4

1 reference

5 December 2017

Vasiliki Mirtsou-Fidani

5

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

European Neuropsychopharmacology

5 December 2017

published in

1 reference

5 December 2017

volume

14

1 reference

5 December 2017

issue

1

1 reference

5 December 2017

page(s)

39-44

1 reference

Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1A2-null mice

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Factors affecting smoking in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Schizophrenia and smoking: an epidemiological survey in a state hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Effects of smoking on fluphenazine clearance in psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Influence of patient-related variables on clozapine plasma levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Prevalence of smoking among psychiatric outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

The use of caffeine for enzyme assays: a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Analysis of urinary caffeine metabolites to assess biotransformation enzyme activities by reversed-phase high-performance liquid chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

A review of the effects of nicotine on schizophrenia and antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Smoking and malignancy in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Seizures following smoking cessation in a clozapine responder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

How important are gender differences in pharmacokinetics?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Individual changes in clozapine levels after smoking cessation: results and a predictive model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Olanzapine Serum Concentrations in Psychiatric Patients Given Standard Doses: The Influence of Comedication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Cigarette smoking and chlorpromazine disposition and actions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Prevalence of smoking in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

The human hepatic cytochromes P450 involved in drug metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Drug interactions with tobacco smoking. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2803%2900061-0

7 January 2021

10.1016/S0924-977X(03)00061-0

Identifiers

DOI

1 reference

5 December 2017

1 reference